IL-6 signaling is the chain of molecular events triggered when the cytokine interleukin-6 binds to its receptor and activates gene programs inside cells. What makes this particular signaling system fascinating, and frustrating for researchers trying to target it, is that IL-6 operates through two fundamentally different modes: one that keeps the immune system running smoothly and another that can drive chronic disease. Understanding the difference between those two modes has reshaped how scientists think about inflammation and opened doors to more precise therapies.
Two Ways to Send the Same Signal
IL-6 doesn’t just dock onto any cell it bumps into. It needs a specific receptor called IL-6R to get the process started. The catch is that IL-6R sits on the surface of only a limited set of cells, mainly liver cells, certain immune cells, and some types of epithelial cells.1PubMed. Dissecting Interleukin-6 Classic- and Trans-Signaling in Inflammation and Cancer When IL-6 binds to IL-6R on one of these cells, the resulting pair then grabs onto a second receptor subunit called gp130, which is found on nearly every cell in the body. That receptor pairing kicks off what’s called classical signaling. It’s the default, tidy version of the process.
Trans-signaling works differently. IL-6R can be clipped off the cell surface by enzymes known as ADAM proteases, creating a free-floating soluble form (sIL-6R).2PubMed Central. Shedding of Endogenous Interleukin-6 Receptor (IL-6R) Is Governed by A Disintegrin and Metalloproteinase (ADAM) Proteases while a Full-length IL-6R Isoform Localizes to Circulating Microvesicles IL-6 can bind to this soluble receptor while both are drifting through the bloodstream or tissue fluid. The IL-6/sIL-6R complex then latches onto gp130 on cells that never had IL-6R on their surface in the first place, switching on signaling in cells that would normally be blind to IL-6. Researchers have also found that full-length IL-6R can hitch a ride on tiny membrane bubbles called microvesicles, providing yet another route for soluble receptor generation.3PubMed Central. Shedding of Endogenous Interleukin-6 Receptor (IL-6R) Is Governed by A Disintegrin and Metalloproteinase (ADAM) Proteases while a Full-length IL-6R Isoform Localizes to Circulating Microvesicles
This distinction matters because classical and trans-signaling activate overlapping but different internal programs. In studies on blood vessel lining cells, classical signaling mainly triggered growth and survival pathways, while trans-signaling additionally activated a transcription factor called STAT3 on top of those same pathways.4PubMed. Overlapping and distinct biological effects of IL-6 classic and trans-signaling in vascular endothelial cells The general consensus in the field is that classical signaling tends to be protective and homeostatic, while trans-signaling is primarily responsible for IL-6’s inflammatory, disease-promoting effects. That’s a simplification, but it’s the framing that has guided drug development.
How the Signal Gets Inside the Cell
Whether IL-6 arrives through classical or trans-signaling, the actual signal passes through gp130. The crystal structure of the active signaling complex, solved at 3.65 angstrom resolution, revealed that IL-6, IL-6R, and gp130 assemble into a hexamer: two copies each of all three molecules locked together through ten interlocking contact points.5PubMed. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex The assembly happens in a specific order. IL-6 first binds IL-6R, and the pair is then presented to gp130 in the right geometry to snap into the final hexamer. Only once this hexamer forms does gp130 send signals into the cell.
Once activated, gp130 sets off a cascade inside the cell. The primary route runs through enzymes called JAK kinases (particularly JAK1), which latch onto gp130 and then activate STAT transcription factors. Once activated, STAT molecules pair up, travel into the nucleus, and switch on target genes.6Portland Press (Biochemical Journal). Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway STAT3 is the star of this show: its activation drives many of the inflammatory and growth-related effects attributed to IL-6.
But gp130 also branches off into other pathways. The same receptor can trigger the MAPK/ERK pathway, which influences cell growth and differentiation, and the PI3K/AKT pathway, which promotes cell survival. Research in neurons showed that IL-6 protects against excitotoxic damage through all three of these routes simultaneously.7PubMed Central. Neuroprotection of interleukin-6 against NMDA-induced neurotoxicity is mediated by JAK/STAT3, MAPK/ERK, and PI3K/AKT signaling pathways Work in heart muscle cells demonstrated that the MAPK and PI3K arms can even function without JAK/STAT activation at all, triggering cell growth and protective enzyme production on their own.8PubMed Central. p42/p44-MAPK and PI3K are sufficient for IL-6 family cytokines/gp130 to signal to hypertrophy and survival in cardiomyocytes in the absence of JAK/STAT activation So gp130 isn’t channeling all its information through a single wire. The cell type, the signaling mode, and the context all determine which combination of pathways fires.
The Built-In Off Switch
A signaling system this powerful needs a brake, and IL-6 signaling has one built into its own output. When STAT3 gets activated and enters the nucleus, one of the genes it switches on encodes a protein called SOCS3. SOCS3 then circles back and physically blocks both gp130 and the JAK kinases that started the cascade, shutting down the signal.9PubMed Central. Inhibition of IL-6 family cytokines by SOCS3 It’s an elegant feedback loop: the signal creates its own silencer. SOCS3 controls both how long IL-6 signaling lasts and how strong the biological response becomes.10PubMed Central. SOCS3: An essential physiological inhibitor of signaling by interleukin-6 and G-CSF family cytokines
This feedback loop becomes important when thinking about disease. In healthy tissue, a burst of IL-6 gets turned off cleanly by SOCS3 within hours. In chronic inflammatory conditions, the sheer volume of IL-6 can overwhelm the brake, or mutations and epigenetic changes in the SOCS3 gene can weaken it. The result is persistent signaling that keeps feeding inflammatory gene programs long after the initial trigger has gone.
What IL-6 Does in the Liver
The liver is one of IL-6’s primary targets, and the relationship there illustrates both the cytokine’s protective role and its potential for harm. During an infection or injury, IL-6 reaches the liver (which is rich in membrane-bound IL-6R) and triggers what’s called the acute-phase response. Within hours, liver cells start pumping out a suite of emergency proteins. More than half of the detectable acute-phase proteins in primary human liver cells increase after IL-6 stimulation, including C-reactive protein (CRP), haptoglobin, fibrinogen chains, and lipopolysaccharide-binding protein.11Cell Systems. Non-opioid analgesics alter IL-6 signaling and hepcidin expression in liver cells These proteins help with clotting, neutralizing pathogens, and cleaning up damage.
One acute-phase protein worth singling out is hepcidin, the master regulator of iron metabolism. Hepcidin locks iron inside cells and out of the bloodstream, starving bacteria of the iron they need to grow. IL-6 is the primary trigger for hepcidin production: it dramatically induces hepcidin gene expression, whereas other inflammatory cytokines do not.12Blood. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein This is useful during a short infection. But when IL-6 stays elevated chronically, the persistent hepcidin signal traps iron inside cells and away from red blood cell production, which is one reason people with long-term inflammatory diseases often develop anemia.
The interplay between IL-6 and other cytokines in the liver is also more nuanced than it first appears. IL-1β, another major inflammatory cytokine, reshapes the acute-phase output that IL-6 drives. The combination of IL-6 and IL-1β suppresses some acute-phase proteins while dramatically boosting others, including CRP and hepcidin.13PubMed. Hepatic acute phase proteins–regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-κB-dependent signaling The liver’s response to inflammation is not simply “more IL-6 equals more of everything.” It depends on the cytokine cocktail present.
IL-6 from Exercising Muscles
One of the more counterintuitive findings in IL-6 research is that skeletal muscle is a major source of the cytokine during exercise. Contracting muscles produce and release substantial amounts of IL-6, earning it the label “myokine” in this context.14PubMed Central. Interleukin-6 myokine signaling in skeletal muscle: a double-edged sword? After prolonged exercise, circulating IL-6 can spike to levels many times higher than resting values, yet this spike is associated with beneficial metabolic effects rather than harmful inflammation.
The explanation lies partly in context. Exercise-derived IL-6 appears in an anti-inflammatory hormonal environment. It enhances fat breakdown, improves glucose uptake, and helps regulate energy balance.15PubMed Central. Interleukin-6 myokine signaling in skeletal muscle: a double-edged sword? The spike is also temporary: it rises fast, drives metabolic changes, and then drops. This acute, pulsatile pattern stands in sharp contrast to the low-grade, constant elevation of IL-6 seen in obesity and chronic disease. The same molecule behaves very differently depending on whether it arrives in a short burst from active muscle or drips steadily from inflamed fat tissue.
Shaping Immune Cell Identity
Beyond its metabolic and inflammatory roles, IL-6 acts as an identity signal for developing immune cells. When a naïve T cell encounters an antigen and begins to specialize, the cytokines present in its environment determine what kind of T cell it becomes. IL-6 has emerged as a non-redundant factor for driving the development of two particular T cell types: Th17 cells, which defend against fungal and bacterial infections at mucosal surfaces, and T follicular helper cells, which help B cells produce antibodies.16PubMed Central. Role of IL-6 in the commitment of T cell subsets “Non-redundant” means no other cytokine can substitute for IL-6 in this role. Without it, these cell types don’t form properly.
This is relevant to both health and disease. Th17 cells are essential for barrier immunity, but when overproduced, they drive autoimmune tissue damage. The link between IL-6 trans-signaling and excessive Th17 expansion helps explain why blocking trans-signaling specifically has become such an attractive therapeutic goal.
When Chronic IL-6 Drives Disease
The split between acute, beneficial IL-6 and chronic, harmful IL-6 plays out most clearly in metabolic disease. Adipose tissue contributes up to about a third of circulating IL-6 in people with obesity, and this steady background level creates problems in the liver.17PubMed. Interleukin-6 and insulin resistance Persistent IL-6 signaling in liver cells activates the same SOCS3 feedback protein that’s supposed to shut off IL-6 signaling, but SOCS3 also happens to block insulin receptor signaling. So chronically elevated IL-6 leads to chronically elevated SOCS3, which interferes with insulin’s ability to do its job.18PubMed. Role of Interleukin-6 in Development of Insulin Resistance and Type 2 Diabetes Mellitus The very molecule that turns off IL-6 turns off insulin signaling too, and that crosswired feedback is a major contributor to insulin resistance in obesity.
In autoimmune diseases, trans-signaling appears to be the dominant culprit. Inflammatory bowel disease provides a well-studied example: the evidence strongly supports the idea that disease development and persistence rely on increased formation of IL-6/sIL-6R complexes that activate gp130 on T cells via trans-signaling.19PubMed. Interleukin-6 trans-signaling in inflammatory bowel disease Those T cells, in turn, resist normal programmed death and keep the inflammatory cycle going.
IL-6 in Cytokine Storms and Severe Infection
IL-6’s role in cytokine release syndrome became widely known during the COVID-19 pandemic. In severe infections, the immune system can lose its usual checks and balances, leading to a runaway loop where immune cells produce enormous amounts of inflammatory cytokines, which recruit more immune cells, which produce more cytokines. IL-6 is a central player in this escalation.20PubMed Central. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality The logic of blocking it during a cytokine storm is straightforward: cut one of the main amplifiers in the loop, and the whole cascade should lose steam.
Cytokine release syndrome is not unique to infections. It also occurs as a side effect of certain cancer immunotherapies, including CAR-T cell therapy, and IL-6 inhibitors have been evaluated in those settings as well.21PubMed. Interleukin-6 cytokine: An overview of the immune regulation, immune dysregulation, and therapeutic approach
Cancer and the Tumor Microenvironment
Inside tumors, IL-6 signaling through JAK/STAT3 is frequently overactive. This dysregulated pathway promotes cancer cell growth, survival, blood vessel formation to feed the tumor, and metastasis by altering the local tumor microenvironment.22PubMed Central. Insights into IL-6/JAK/STAT3 signaling in the tumor microenvironment: Implications for cancer therapy Both tumor cells themselves and the surrounding immune and stromal cells can produce IL-6, creating a self-sustaining signaling loop within the tumor. STAT3 activation in particular suppresses the anti-tumor immune response while simultaneously driving tumor cell proliferation, making it a double problem.
The Brain, Sickness Behavior, and Aging
IL-6 also has effects in the central nervous system. Studies in mice lacking the IL-6 gene showed that these animals had a blunted sickness response to bacterial toxins and to IL-1β, both when the challenge came from outside the brain and when it was delivered directly into the brain.23PubMed. Role of IL-6 in cytokine-induced sickness behavior: a study with IL-6 deficient mice The fatigue, appetite loss, and social withdrawal you feel when sick are partly mediated by IL-6 acting on the brain. In the short term, this sickness behavior is adaptive: it forces rest and conserves energy for fighting infection. Chronically elevated IL-6 in the brain, however, has been linked to depression and cognitive decline.
Aging ties many of these threads together. Senescent cells, which have stopped dividing but refuse to die, secrete a cocktail of inflammatory molecules known as the senescence-associated secretory phenotype. IL-6 is a prominent member of that cocktail.24PubMed Central. Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation As senescent cells accumulate with age, the background level of IL-6 creeps up, contributing to a state sometimes called “inflammaging.” This low-grade chronic inflammation is thought to accelerate cardiovascular disease, metabolic dysfunction, and neurodegeneration in older adults. The same pathway from the NLRP3 inflammasome to IL-1 to IL-6 to CRP that drives acute-phase responses in the liver also appears to be a key chain in the development of atherosclerosis over a lifetime.25Circulation Research. Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease
Drugs That Block IL-6 Signaling
The main therapeutic strategy has been to block IL-6 signaling globally. Tocilizumab and sarilumab are antibodies that bind IL-6R, preventing IL-6 from engaging its receptor at all. Siltuximab takes a different approach and binds IL-6 itself. All three have been used in rheumatoid arthritis, cytokine release syndrome, and severe COVID-19.26PubMed Central. Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome Structural work has shown that both tocilizumab and sarilumab compete for the same site on IL-6R where IL-6 normally binds, physically blocking the cytokine from docking.27PubMed. Structural insights into IL-6 signaling inhibition by therapeutic antibodies
These drugs work, but they block both classical and trans-signaling indiscriminately. That means they shut down the protective, homeostatic arm along with the inflammatory one. Comparing the two receptor blockers head to head reveals this nuance: tocilizumab and siltuximab produce distinct effects on T cells in treated patients. Tocilizumab reduced markers on T follicular helper cells and dampened certain T cell activation, while siltuximab actually reversed T cell resistance to regulatory suppression and increased production of several immunomodulatory cytokines.28The Journal of Clinical Investigation. IL-6–targeted therapies to block the cytokine or its receptor drive distinct alterations in T cell function In other words, how you block IL-6 matters, and different blocking strategies rewire the immune system in different ways.
Targeting Trans-Signaling Alone
The recognition that trans-signaling drives most of IL-6’s pathological effects while classical signaling is often protective has fueled development of more selective inhibitors. The most advanced of these is olamkicept (also called sgp130Fc), a decoy protein engineered from the soluble form of gp130 itself. It mops up IL-6/sIL-6R complexes in circulation, blocking trans-signaling, while leaving IL-6 bound to membrane-anchored IL-6R untouched. In a clinical trial of patients with active inflammatory bowel disease, olamkicept showed efficacy in preclinical models without signs of the broad immunosuppression seen with total IL-6 blockade.29PubMed. Therapeutic Interleukin-6 Trans-signaling Inhibition by Olamkicept (sgp130Fc) in Patients With Active Inflammatory Bowel Disease
Newer variants aim to refine this approach even further. One limitation of the original sgp130Fc design is that it also blocks trans-signaling by IL-11, a related cytokine that uses the same gp130 receptor. Researchers have engineered miniaturized chimeric versions fused to a nanobody that specifically traps IL-6/sIL-6R complexes without touching IL-11 signaling.30PubMed. Selective inhibition of IL-6 trans-signaling by a miniaturized, optimized chimeric soluble gp130 inhibits TH17 cell expansion This level of specificity could make it possible to dampen the inflammatory arm of IL-6 without compromising either its protective signaling or the functions of related cytokines.
The Larger gp130 Family
IL-6 is not the only cytokine that signals through gp130. It belongs to a family of cytokines, including IL-11, IL-27, leukemia inhibitory factor (LIF), oncostatin M, and others, all of which use gp130 as a required component of their receptor complexes.31PubMed Central. Structural insights into the assembly of gp130 family cytokine signaling complexes This shared use of a single receptor subunit is one reason these cytokines have overlapping biological activities: they funnel through a common signal transduction pathway.32PubMed. Signal transduction through gp130 that is shared among the receptors for the interleukin 6 related cytokine subfamily
Genetic variants in the gene encoding gp130 have been linked to a range of clinical conditions, reflecting the receptor’s involvement in so many different cytokine systems.33PubMed Central. The Human GP130 Cytokine Receptor and Its Expression-an Atlas and Functional Taxonomy of Genetic Variants This interconnectedness is a double-edged consideration for drug design. Any therapy that targets gp130 directly risks disrupting signaling from the entire family, while therapies aimed specifically at IL-6 or IL-6R can leave the rest of the family’s functions intact.
Measuring IL-6 at the Bedside
Because IL-6 rises so quickly during inflammatory emergencies, there has been strong interest in using it as a real-time biomarker in hospitals. Standard lab tests for infection and inflammation, like CRP, reflect IL-6 activity with a delay of many hours because CRP is a downstream product that the liver makes in response to IL-6. Measuring IL-6 directly gives clinicians an earlier signal. Point-of-care assays that can return IL-6 results in minutes rather than hours have been developed and show good correlation with established laboratory platforms.34PubMed Central / Future Science. Development of an IL-6 point-of-care assay: utility for real-time monitoring and management of cytokine release syndrome and sepsis In conditions like sepsis and cytokine release syndrome, where the difference between early and late intervention can be life or death, a rapid IL-6 readout could help guide decisions about when to deploy therapies like tocilizumab.
An Ancient Signaling Architecture
The gp130 receptor system is evolutionarily old. Comparative studies of class I cytokine receptors found that sea squirts, invertebrate relatives of vertebrates, already possess a receptor with clear homology to gp130. By the time zebrafish diverged from the lineage that would become mammals, 36 class I cytokine receptors were present, with representatives from all five structural groups found in mammals. From that diversity, researchers have traced roughly 27 core receptor genes back to the last common ancestor of bony fish and mammals.35PubMed Central. Evolution of Class I cytokine receptors The gp130 system, in other words, predates the vertebrate immune system as we know it. The machinery that IL-6 plugs into was already in place hundreds of millions of years ago, and vertebrate evolution has layered increasing complexity onto it since.